- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07911202
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Sphenopalatine Ganglion Block for Functional Endoscopic Sinus Surgery
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Sphenopalatine Ganglion Block in Patients Undergoing Functional Endoscopic Sinus Surgery
This prospective, randomized, double-blind, controlled trial will compare the efficacy and safety of dexmedetomidine versus dexamethasone as adjuvants to bupivacaine in ultrasound-guided bilateral sphenopalatine ganglion block for adult patients (18-60 years, ASA I-II) undergoing elective functional endoscopic sinus surgery (FESS) under general anesthesia. Participants will be randomly allocated in a 1:1:1 ratio to receive bupivacaine alone, bupivacaine plus dexmedetomidine, or bupivacaine plus dexamethasone. The study will assess postoperative pain scores, duration of analgesia, total analgesic consumption, and intraoperative hemodynamic parameters, in addition to adverse effects.
Visão geral do estudo
Status
Descrição detalhada
Background: Postoperative pain after functional endoscopic sinus surgery (FESS) is often significant, and conventional management relies on opioids and NSAIDs, which carry potential side effects. Ultrasound-guided sphenopalatine ganglion block (SPGB) with bupivacaine provides regional analgesia, but its duration may be insufficient. Dexmedetomidine and dexamethasone are adjuvants known to prolong analgesia and reduce analgesic requirements, yet direct comparative evidence for ultrasound-guided SPGB in FESS is limited.
Design: Prospective, randomized, double-blind, controlled clinical trial conducted at the ENT department, Sohag University Hospital. Eligible patients (age 18-60 years, ASA I-II, elective FESS under general anesthesia) who provide written informed consent will be randomized 1:1:1 using a computer-generated sequence, with allocation concealed in sequentially numbered, opaque, sealed envelopes. Patients with allergy to local anesthetics, coagulopathy or anticoagulant use, anatomical nasal deformities obstructing access, or who refuse participation will be excluded.
Interventions: All patients will receive ultrasound-guided bilateral SPGB with a total volume of 10 mL (5 mL per side) after induction of general anesthesia.
- Group A (control): 8 mL bupivacaine 0.5% plus 2 mL normal saline.
- Group B: 8 mL bupivacaine 0.5% plus dexmedetomidine 1 µg/kg diluted with normal saline to 2 mL.
- Group C: 8 mL bupivacaine 0.5% plus dexamethasone 8 mg (2 mL).
Patients, anesthesiologists responsible for intraoperative and postoperative assessment, surgeons, and data analysts will be blinded to group allocation.
Anesthetic technique: General anesthesia will be induced with propofol 2.5 mg/kg and fentanyl 1 µg/kg, and intubation facilitated with atracurium 0.5 mg/kg. Anesthesia will be maintained with isoflurane in oxygen and atracurium boluses, with mechanical ventilation to keep end-tidal CO2 at 35-45 mmHg.
Outcomes: Postoperative pain scores, duration of analgesia, total analgesic consumption, intraoperative hemodynamic measurements, and adverse effects.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Nardin Ehab Halim, M.B.B.Ch
- Número de telefone: 01012631360
- E-mail: nardinehab12@gmail.com
Locais de estudo
-
-
Sohag Governorate
-
Sohag, Sohag Governorate, Egito
- Sohag university hospital
-
Contato:
- Nardin Ehab Halim, MBBCH
- Número de telefone: 01012631360
- E-mail: nardinehab12@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 18-60 years.
- Elective FESS under general anesthesia.
- ASA Physical Status I-II
Exclusion Criteria:
- Allergy to local anesthetics
- Coagulopathy or use of anticoagulants
- Anatomical nasal deformities obstructing access
- Patient refusal
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Group A: Bupivacaine
Patients will receive ultrasound-guided bilateral sphenopalatine ganglion block with 8 mL of bupivacaine 0.5% plus 2 mL of normal saline, giving a total volume of 10 mL (5 mL per side), after induction of general anesthesia. |
2 mL of normal saline 0.9% added to bupivacaine 0.5% (8 mL) in the sphenopalatine ganglion block to maintain a total volume of 10 mL (5 mL per side) and ensure blinding. |
|
Experimental: Group B: Bupivacaine + Dexmedetomidine
Patients will receive ultrasound-guided bilateral sphenopalatine ganglion block with 8 mL of bupivacaine 0.5% plus dexmedetomidine 1 µg/kg diluted with normal saline to 2 mL, giving a total volume of 10 mL (5 mL per side), after induction of general anesthesia. |
Patients will receive ultrasound-guided bilateral sphenopalatine ganglion block with 8 mL of bupivacaine 0.5% plus dexmedetomidine 1 µg/kg diluted with normal saline 0.9% to a volume of 2 mL, giving a total volume of 10 mL (5 mL per side) |
|
Experimental: Group C: Bupivacaine + Dexamethasone
Patients will receive ultrasound-guided bilateral sphenopalatine ganglion block with 8 mL of bupivacaine 0.5% plus dexamethasone 8 mg (2 mL), giving a total volume of 10 mL (5 mL per side), after induction of general anesthesia. |
Patients will receive ultrasound-guided bilateral sphenopalatine ganglion block with 8 mL of bupivacaine 0.5% plus dexamethasone 8 mg (2 mL), giving a total volume of 10 mL (5 mL per side) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postoperative Pain Intensity Assessed by the Visual Analogue Scale (VAS)
Prazo: At PACU arrival and at 2, 4, 6, 12, and 24 hours postoperatively
|
Postoperative pain intensity will be assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be compared among the three study groups.Unit of measure : score on a scale |
At PACU arrival and at 2, 4, 6, 12, and 24 hours postoperatively
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to First Rescue Analgesia
Prazo: From the end of surgery until the first rescue analgesic dose, within the first 24 hours postoperatively.
|
The time from the end of surgery to the first postoperative rescue analgesic request or administration. Unit of measure: minutes. |
From the end of surgery until the first rescue analgesic dose, within the first 24 hours postoperatively.
|
|
Incidence of Emergence Agitation
Prazo: During emergence from general anesthesia and at PACU arrival
|
Emergence agitation is defined as a Richmond Agitation-Sedation Scale (RASS) score of +1 or higher. The number of participants with emergence agitation will be reported. Unit of measure: number of participants. |
During emergence from general anesthesia and at PACU arrival
|
|
Intraoperative Mean Arterial Pressure
Prazo: From baseline assessment before induction of general anesthesia until the end of surgery
|
Mean arterial pressure (MAP) will be recorded at baseline, after induction of general anesthesia, and every 10 minutes intraoperatively until the end of surgery. Unit of measure: mmHg. |
From baseline assessment before induction of general anesthesia until the end of surgery
|
|
Intraoperative Heart Rate
Prazo: From baseline before induction of general anesthesia until the end of surgery.
|
Heart rate (HR) will be recorded at baseline, after induction of general anesthesia, and every 10 minutes intraoperatively until the end of surgery. Unit of measure: beats per minute. |
From baseline before induction of general anesthesia until the end of surgery.
|
|
Number of Postoperative Rescue Analgesic Doses
Prazo: First 24 hours postoperatively
|
The total number of postoperative rescue analgesic doses administered, regardless of drug type, during the first 24 hours after surgery.Unit of measure: number of doses |
First 24 hours postoperatively
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Dor
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Complicações pós-operatórias
- Processos Patológicos
- Confusão
- Manifestações Neurocomportamentais
- Distúrbios Neurocognitivos
- Delírio
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Delírio de emergência
- Dor, Pós-operatório
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Preparações farmacêuticas
- Azoles
- Compostos policíclicos
- Imidazoles
- Anilides
- Amidas
- Compostos de anilina
- Aminas
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- Esteróides, fluorados
- Soluções cristalóides
- Soluções isotônicas
- Soluções
- Pregadienetriols
- Dexametasona
- Bupivacaína
- Dexmedetomidina
- Solução salina
Outros números de identificação do estudo
- Soh-Med-26-10-12MS
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .